RZ-358 is a Monoclonal Antibody owned by Rezolute, and is involved in 7 clinical trials, of which 5 were completed, 1 is ongoing, and 1 is planned.
RZ-358 is an antagonist (deactivator) of the insulin receptor. Inhibition of the insulin receptor mitigates the insulin-induced hypoglycemia by inhibiting the downstream signaling of insulin.
The revenue for RZ-358 is expected to reach a total of $1.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the RZ-358 NPV Report.
RZ-358 (XOMA-358) is under development for the treatment of hyperinsulinemic hypoglycemia post gastric bypass surgery, and hypoglycemia associated with congenital hyperinsulinism. The drug candidate is a fully human monoclonal antibody which is administered through intravenous route as a solution. It is a fully human negative allosteric selective insulin receptor modulator (SIRMs) antibody derived from the XMet platform. It was also under development for the treatment of insulinomas.
Rezolute formerly, AntriaBio Inc, is a clinical-stage biopharmaceutical company that carries out the development of innovative drug therapies for the treatment of metabolic diseases related to chronic glucose imbalance. Its pipeline product portfolio includes RZ358 which is an intravenous monoclonal antibody. RZ358 is used for the treatment of conditions characterized by excessive insulin levels and is developing to treat hyperinsulinism and low blood sugar characteristic of diseases such as congenital hyperinsulinism. The company also offers RZ402 which is a potent plasma kallikrein inhibitor used for the treatment of diabetic macular edema (DME). Rezolute is headquartered in Redwood City, California, the US.
The operating loss of the company was US$22.4 million in FY2021, compared to an operating loss of US$20.5 million in FY2020. The net loss of the company was US$20.9 million in FY2021, compared to a net loss of US$20.3 million in FY2020.
Quick View – RZ-358
|Highest Development Stage|